×

Methods for treatment with bucindolol based on genetic targeting

  • US 8,093,286 B2
  • Filed: 08/13/2007
  • Issued: 01/10/2012
  • Est. Priority Date: 09/14/2004
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:

  • administering bucindolol to the patient if the patient is determined to be homozygous for Arg389 in the β

    1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient.

View all claims
  • 6 Assignments
Timeline View
Assignment View
    ×
    ×